CRISPR

CRISPR1-ldlra

ID

ZDB-CRISPR-170913-2

Name

CRISPR1-ldlra

Previous Names

None

Target

ldlra (1)

Sequence

5' - GGTTGCACTGCCGACTGCCG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
sd52	ldlra

Expression

Gene expression in Wild Types + CRISPR1-ldlra

No data available

Phenotype

Phenotype resulting from CRISPR1-ldlra

No data available

Phenotype of all Fish created by or utilizing CRISPR1-ldlra

Phenotype	Fish	Conditions	Figures
liver hmgcra expression increased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 2 from Liu et al., 2017
vasculature lipid increased amount, abnormal	ldlra^sd52/sd52	high cholesterol	Fig. 5 from Liu et al., 2017
vasculature lipid increased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 3 from Liu et al., 2017
hepatocyte cellular response to lipopolysaccharide disrupted, abnormal	ldlra^sd52/sd52	chemical treatment by injection: lipopolysaccharide	Fig. 6 from Liu et al., 2017
blood plasma lipid amount, ameliorated	ldlra^sd52/sd52	high cholesterol, chemical treatment by diet: lomitapide	Fig. 5 from Liu et al., 2017
whole organism hmgcra expression increased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 3 from Liu et al., 2017
whole organism ldlra expression decreased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 3 from Liu et al., 2017
blood plasma lipid increased amount, abnormal	ldlra^sd52/sd52	high cholesterol, chemical treatment by diet: probucol	Fig. 5 from Liu et al., 2017
vasculature lipid amount, ameliorated	ldlra^sd52/sd52	high cholesterol, chemical treatment by diet: lomitapide	Fig. 5 from Liu et al., 2017
whole organism cholesterol increased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 3 from Liu et al., 2017
blood plasma very-low-density lipoprotein decreased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 2 from Liu et al., 2017
blood plasma low-density lipoprotein increased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 2 from Liu et al., 2017
whole organism triglyceride increased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 3 from Liu et al., 2017
liver ldlra expression decreased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 2 from Liu et al., 2017
blood plasma cholesterol increased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 2 from Liu et al., 2017
caudal vein lipid increased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 4 from Liu et al., 2017
whole organism fasn expression increased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 3 from Liu et al., 2017
vasculature lipid increased amount, abnormal	ldlra^sd52/sd52	high cholesterol, chemical treatment by diet: probucol	Fig. 5 from Liu et al., 2017
blood plasma lipid increased amount, abnormal	ldlra^sd52/sd52	high cholesterol	Fig. 5 from Liu et al., 2017
caudal vein lipid increased amount, abnormal	ldlra^sd52/sd52	high cholesterol	Fig. 4 from Liu et al., 2017
blood plasma triglyceride increased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 2 from Liu et al., 2017
tolerance induction to lipopolysaccharide disrupted, abnormal	ldlra^sd52/sd52	chemical treatment by injection: lipopolysaccharide	Fig. S3 from Liu et al., 2017
blood plasma lipid increased amount, abnormal	ldlra^sd52/sd52	standard conditions	Fig. 5 from Liu et al., 2017

Citations